NEUROPROTECTIVE POTENTIAL OF ADIPOSE MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES ON DAMAGED MOTONEURONS
Caprioli M1, Sganzerla D1, Scambi I1, Virla F1, Grazioli N2, Greco N2, Turano E1 and Mariotti R1 | 1Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Italy; 2Department of Engineering for Innovation Medicine, University of Verona, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Intranasal delivery represents a non-invasive and promising route to directly target the central nervous system (CNS), as it enables therapeutic agents to bypass the blood–brain barrier and allows repeated administration with low invasiveness. In this context, extracellular vesicles derived from adipose mesenchymal stem cells (ASC-EVs) are gaining increasing attention for their intrinsic neuroprotective and immunomodulatory properties, making them attractive candidates for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). In this study, we established an in vitro epithelial barrier model using RPMI 2650 cells (derived from nasal epithelium carcinoma) cultured on transwell system and coupled with motor neuron-like NSC-34 cells treated with hydrogen peroxide to mimic oxidative stress-induced injury. This setup was designed to investigate the ability of ASC-EVs to cross the epithelial layer, representing the first step of access to the CNS following intranasal administration, and to reach damaged motor neurons. The study also explores the mechanisms underlying epithelial transport by evaluating both transcellular and paracellular routes through the use of selective pathway inhibitors and by monitoring changes in transepithelial electrical resistance (TEER) and junctional integrity. Our findings demonstrate that ASC-EVs are able to traverse the epithelial barrier and reach damaged motor neurons, where they are internalized and exert significant neuroprotective effects. These results provide a mechanistic basis supporting the potential of intranasally delivered ASC-EVs as a non-invasive therapeutic approach for ALS and other neurodegenerative disorders.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
